OBJECTIVE: To review the clinical trials, pharmacologic characteristics, safety, 
and efficacy of the elvitegravir/cobicistat/emtricitabine/tenofovir single 
tablet formulation (Stribild).
DATA SOURCES: Literature searches were performed in MEDLINE (1948-September 
2012) and PubMed (1966-September 2012) using the search terms GS-9137, 
elvitegravir, GS 9350, cobicistat, quad pill, Stribild, and integrase 
inhibitors. Abstracts from HIV/AIDS conferences were reviewed.
STUDY SELECTION AND DATA EXTRACTION: Phase 3 studies evaluating the safety and 
efficacy of Stribild were preferentially evaluated, as well as relevant 
references from the published studies.
DATA SYNTHESIS: Stribild contains complete antiretroviral therapy for HIV-1 
infection in a single tablet. It is the first once-daily therapy option 
available with an integrase inhibitor and a novel pharmacokinetic boosting 
agent. Stribild has shown noninferiority in viral load suppression at 48 weeks 
when compared with dual nucleoside/nucleotide reverse transcriptase inhibitor 
and either a ritonavir-boosted protease inhibitor or nonnucleoside reverse 
transcriptase inhibitor regimen. Stribild was well tolerated, but some patients 
experienced increases in serum creatinine early in treatment that stabilized 
over time.
CONCLUSIONS: Stribild is the first single-tablet regimen for HIV-1 infection 
treatment containing an integrase inhibitor. It is expected to have a prominent 
place in the formularies of health plans providing care for individuals with 
HIV-1 infection.